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LIST	OF	COMMONLY	USED	ACRONYMS	 	
AI/AN	 	 American	Indian/Alaska	Native	
AIDS			 	 Acquired	Immunodeficiency	Syndrome	
API	 	 Asian/Pacific	Islander	
BIDLS	 	 Bureau	of	Infectious	Disease	and	Laboratory	Sciences	
BRFSS	 	 Behavioral	Risk	Factor	Surveillance	System	
CDC	 	 Centers	for	Disease	Control	and	Prevention	
CI	 	 Confidence	Interval	
DOE	 	 Department	of	Education	
HIV					 	 Human	Immunodeficiency	Virus	
HTSX	 	 Heterosexual	Sex	
IDU		 	 Injection	Drug	Use	
MDPH			 Massachusetts	Department	of	Public	Health	
MSM	 	 Men	who	have	sex	with	Men	
N	 	 Number	
NH	 	 Non-Hispanic	
NIR	 	 No	Identified	Risk	
Pres.	HTSX	 Presumed	Heterosexual	Sex	
PWID	 	 People	who	Inject	Drugs	
STD	 	 Sexually	Transmitted	Disease	
STI	 	 Sexually	Transmitted	Infection	
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Executive	Summary	2017	
	
The	2017	Integrated	HIV/AIDS,	STD,	and	Viral	Hepatitis	Surveillance	Report	provides	data	on	
infections	reported	to	the	Massachusetts	Department	of	Public	Health	(MDPH)	Bureau	of	
Infectious	Disease	and	Laboratory	Sciences	by	healthcare	providers	and	laboratories	per	
regulation	(105	CMR	300.000).	This	report	focuses	on	a	subset	of	these	diseases:		
• Chlamydia	
• Gonorrhea	
• Hepatitis	B	
• Hepatitis	C	
• HIV/AIDS	
• Syphilis	
	
The	intended	audience	for	this	annual	surveillance	report	includes	the	clinicians	and	laboratory	
professionals	who	report	cases,	as	well	as	the	community	organizations,	local	public	health	
departments,	advocates,	policymakers,	and	researchers	who	are	interested	in	the	health	of	
Massachusetts	residents.	
	
Key	highlights	in	2017		
	
Chlamydia,	gonorrhea,	and	syphilis:	
• Chlamydia	continues	to	be	the	most	commonly	reported	infectious	disease,	now	
with	approximately	29,000	cases	reported	annually.	
• Gonorrhea	increased	by	58%	from	2016	(N=4,617)	to	2017	(N=7,306).		
• Gonorrhea	is	now	clearly	reported	disproportionately	in	men,	among	whom	rates	
have	more	than	quadrupled	over	the	last	decade	(from	32.0	per	100,000	in	2008	to	
150.5	per	100,000	in	2017).	However,	the	rate	among	women	also	increased	(from	
33.2	per	100,000	in	2008	to	69.8	per	100,000	in	2017).	
• The	incidence	rate	of	infectious	syphilis	(primary,	secondary,	and	early	non-primary	
non-secondary	syphilis)	increased	to	a	ten-year	high	of	15.9	per	100,000	population	
in	2017.		Syphilis	continues	to	disproportionally	affect	men,	reflecting	an	ongoing	
epidemic	among	men	who	have	sex	with	men.	
• Young	adults	(ages	15–29	years)	have	the	highest	rates	of	chlamydia	and	gonorrhea,	
compared	to	individuals	in	other	age	groups.	
	
HIV/AIDS:1	
• The	number	of	HIV	infection	diagnoses	decreased	by	16%	from	2007	(N=766)	to	
2016	(N=641).	The	number	of	persons	known	to	be	living	with	HIV/AIDS	in	
Massachusetts	increased	23%	between	2007	(N=18,201	and	2016	(N=22,329)	due	to	
improved	survival	and	lower	rates	of	death.	
• Black	NH	and	Hispanic/Latino	residents	had	significantly	higher	rates	of	HIV	infection	
diagnoses	compared	to	white	NH	residents.	Disparities	were	most	notable	among	
                                                
1	Due	to	the	extensive	follow-up	required	to	verify	date	of	diagnosis,	all	HIV/AIDS	data	reflect	HIV	infection	
diagnosed	through	2016.	
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women,	as	51%	of	women	newly	diagnosed	between	2014	and	2016	were	black	NH	
and	22%	were	Hispanic/Latina.	
• Male-to-male	sex	remained	the	single	most	frequently	reported	exposure	mode	
among	newly	diagnosed	cases	of	HIV	infection,	and	represented	63%	of	newly	
diagnosed	cases	among	men	during	2014	to	2016.	
• The	number	of	individuals	diagnosed	with	HIV	infection	who	inject	drugs	decreased	
by	68%	from	99	in	2007	to	a	ten-year	low	of	30	in	2014,	then	increased	to	50	in	2015	
and	67	in	2016.	
	
Hepatitis	B	and	C:	
• Reported	confirmed	cases	of	chronic	hepatitis	B	continued	to	decline,	due	in	large	
part	to	near-universal	infant	immunization	in	Massachusetts	and	the	United	States.		
• An	average	of	over	8,200	confirmed	and	probable	hepatitis	C	cases	were	reported	in	
each	of	the	past	ten	years	(2008	to	2017).		
• There	continued	to	be	an	increase	of	hepatitis	C	cases	reported	among	adolescents	
(age	15–19	years)	and	young	adults	(age	20–29	years),	reflecting	ongoing	
transmission	among	young	people	injecting	opioids.	
	
This	report	was	developed	by	the	following	MDPH	staff:	
	
Katherine	Hsu,	MD,	MPH,	Medical	Director,	Division	of	STD	Prevention	and	HIV/AIDS	
Surveillance	
Betsey	John,	MPH,	Director,	HIV/AIDS	and	STD	Surveillance	
Lauren	Molotnikov,	MPH,	Senior	Surveillance	Epidemiologist,	Division	of	STD	Prevention		
Shauna	Onofrey,	MPH,	Viral	Hepatitis	Surveillance	Coordinator,	Division	of	Epidemiology	and	
Immunization	
Kathleen	Roosevelt,	MPH,	Director,	Division	of	STD	Prevention	and	HIV	Surveillance	
Patricia	Kludt,	MPH,	Director,	Epidemiology	Program		
Gillian	Haney,	MPH,	Director,	Office	of	Integrated	Surveillance	and	Informatics	Services	
H.	Dawn	Fukuda,	ScM,	Director,	Office	of	HIV/AIDS	
Catherine	Brown,	DVM,	PhD,	State	Epidemiologist,	Bureau	of	Infectious	Disease	and	Laboratory	
Sciences	
Larry	Madoff,	MD,	Medical	Director,	Bureau	of	Infectious	Disease	and	Laboratory	Sciences	
Kevin	Cranston,	MDiv,	Assistant	Commissioner	and	Director,	Bureau	of	Infectious	Disease	and	
Laboratory	Sciences	
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CHLAMYDIA	
	
	
	
• 29,202	cases	of	chlamydia	were	reported	in	Massachusetts	in	2017,	making	it	the	most	
frequently	reported	infection	in	the	Commonwealth.				
• The	total	number	of	reported	chlamydia	cases	increased	by	67%	from	17,441	in	2008	to	
29,202	in	2017.	
• In	2017,	the	age-adjusted	chlamydia	incidence	rate	among	women	(551.9	per	100,000)	
was	nearly	twice	as	high	as	the	rate	among	men	(311.8	per	100,000).	
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• Chlamydia	cases	continue	to	be	reported	diffusely,	with	additional	concentration	in	urban	
areas.	
• The	five	cities	with	the	highest	chlamydia	incidence	rates	were	Lawrence	(1,209.8	per	
100,000),	Brockton	(1,183.2	per	100,000),	Provincetown,	(1,155.7	per	100,000),	Springfield	
(1,063.6	per	100,000),	and	Boston	(927.0	per	100,000).	
• In	2017,	the	statewide	chlamydia	incidence	rate	of	421.8	per	100,000	population	was	lower	
than	the	national	rate	of	528.8	per	100,000.2		
• Massachusetts	ranked	the	tenth	lowest	in	chlamydia	incidence	rate	among	the	50	states.	2			
	 	
                                                
2	Centers	for	Disease	Control	and	Prevention.	Sexually	Transmitted	Disease	Surveillance	2017.	Atlanta:	U.S.	Department	of	
Health	and	Human	Services;	2018	
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• The	chlamydia	incidence	rate	remained	highest	among	adolescents	and	young	adults.		
• In	2017,	the	chlamydia	incidence	rate	among	young	adults	(ages	20–24)	was	over	five	times	
higher	than	the	statewide	rate	among	all	ages	(2,298.9	compared	to	421.8	per	100,000).		
• The	rate	among	adolescents	(ages	15–19)	was	over	three	times	higher	than	the	statewide	
rate	among	all	ages	(1,463.9	compared	to	421.8	per	100,000).	
	
Additional	information	about	chlamydia	and	other	STDs	is	available	online	at	
www.mass.gov/dph/cdc/std.	
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GONORRHEA	
	
	
	
• The	total	number	of	reported	gonorrhea	cases	increased	by	72%	from	2,077	in	2008	to	
7,306	in	2017.		
• Between	2008	and	2017,	the	age-adjusted	gonorrhea	incidence	rate	reported	among	men	
more	than	quadrupled	(from	32.0	per	100,000	to	150.5	per	100,000).	The	gonorrhea	
incidence	rate	among	men	is	now	more	than	double	the	rate	among	women	(69.8	per	
100,000).	
• The	age-adjusted	gonorrhea	incidence	rate	reported	among	women	increased	by	85%	from	
37.7	per	100,000	in	2016	to	69.8	per	100,000	in	2017.	 	
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• Gonorrhea	cases	continued	to	be	clustered	in	urban	areas	in	2017.	
• The	five	cities	with	the	highest	gonorrhea	incidence	rates	rates	were	Provincetown	(1,053.7	
per	100,000),	Springfield	(390.7	per	100,000),	Holyoke	(310.9	per	100,000),	Boston	(299.6	
per	100,000),	and	Brockton	(299.6	per	100,000).	
• In	2017,	the	statewide	gonorrhea	incidence	rate	of	107.0	per	100,000	was	lower	than	the	
national	rate	of	171.9	per	100,000.2		
• Massachusetts	ranked	the	13th	lowest	in	gonorrhea	incidence	rate	among	the	50	states.2	
	
	
	
	
2	Centers	for	Disease	Control	and	Prevention.	Sexually	Transmitted	Disease	Surveillance	2017.	Atlanta:	U.S.	Department	of	
Health	and	Human	Services;	2018.	 	
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• The	gonorrhea	incidence	rate	among	young	adults	(ages	20–24	and	25–29)	has	been	
increasing	since	2009,	but	has	increased	in	all	age	groups	since	2015.		
• In	2017,	the	gonorrhea	incidence	rates	among	young	adults	(ages	20–24	and	25–29)	were	
more	than	three	times	the	statewide	incidence	rate	among	all	ages	(362.1	and	342.3,	
respectively	compared	to	107.0	per	100,000).	
	
Additional	information	about	gonorrhea	and	other	STDs	is	available	online	at	
www.mass.gov/dph/cdc/std.	
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GONORRHEA	–	2016–2017	
	
	
	
• From	2016	to	2017,	the	gonorrhea	incidence	rate	increased	from	67.7	to	106.5	per	
100,000	statewide,	from	101.3	to	149.3	per	100,000	among	men,	and	from	35.9	to	66.1	
per	100,000	among	women.	
• The	overall	gonorrhea	incidence	rate	increased	in	all	counties	except	Dukes	and	
Nantucket	from	2016	to	2017.	The	three	counties	with	the	largest	increases	were	
Hampden	(97.7	to	228.2	per	100,000),	Suffolk	(175.1	to	248.9	per	100,000),	and	
Worcester	(35.1	to	87.5	per	100,000).	
o Among	men,	the	three	counties	with	the	largest	incidence	rate	increases	were	
Hampden	(119.7	to	262.3	per	100,000),	Suffolk	(292.7	to	384.7	per	100,000),	and	
Worcester	(44.1	to	117.5	per	100,000	in	2017).	
o Among	women,	the	two	counties	with	the	largest	incidence	rate	increases	were	
Hampden	(77.1	to	196.2	per	100,000)	and	Suffolk	(64.7	to	121.5	per	100,000).	
Worcester	and	Essex	counties	saw	similar	increases	in	gonorrhea	rates	among	
women.	
	
2017	Integrated	HIV/AIDS,	STD,	and	Viral	Hepatitis	Surveillance	Report	
Massachusetts	Department	of	Public	Health	
	
	 	 	11	
	
	
• From	2016	to	2017,	the	three	age	groups	with	the	largest	increases	in	overall	gonorrhea	
incidence	rate	were	25–29	years	(increase	of	128.4	per	100,000),	20–24	years	(increase	
of	111.0	per	100,000),	and	30–34	years	(increase	of	92.7	per	100,000).	
o Among	men,	the	three	age	groups	with	the	largest	rate	increases	were	also	25–
29	years	(increase	of	148.4	per	100,000),	20–24	years	(increase	of	120.6	per	
100,000),	and	30–34	years	(increase	of	119.4	per	100,000).	
o Among	women	the	three	age	groups	with	the	largest	rate	increases	were	25–29	
years	(increase	of	107.0	per	100,000),	20–24	years	(increase	of	101.8	per	
100,000),	and	15–19	years	(increase	of	75.0	per	100,000).	
• The	only	age	group	where	women	experienced	a	larger	increase	in	gonorrhea	incidence	
rate	compared	to	men	was	15–19	years	(of	75.0	and	49.3	per	100,000,	respectively).	
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SYPHILIS		
	
	
	
• 1,091	infectious	syphilis	(primary,	secondary,	and	early	latent)	cases	were	reported	in	2017.	
• The	total	number	of	reported	infectious	syphilis	cases	in	2017	(N=1,091)	was	nearly	three	
times	the	number	reported	in	2008	(N=366).	
• Between	2008	and	2017,	the	age-adjusted	syphilis	incidence	rate	reported	among	men	
nearly	tripled	(from	11.4	to	31.0	per	100,000).	The	syphilis	incidence	rate	among	men	is	
now	17	times	higher	than	the	rate	among	women	(1.8	per	100,000).	 	
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• The	five	cities	with	the	highest	infectious	syphilis	incidence	rates	were	Provincetown	(543.9	
per	100,000),	Somerville	(66.0	per	100,000),	Boston	(55.2	per	100,000),	Revere	(46.4	per	
100,000),	and	Springfield	(37.9	per	100,000).	
• The	statewide	infectious	syphilis	incidence	rate	increased	from	5.8	per	100,000	in	2008	to	a	
ten-year	high	of	15.9	per	100,000	in	2017.		
• Massachusetts	ranked	the	19th	highest	in	primary	and	secondary	syphilis	incidence	rate	
among	the	50	states.2	
	
	
	
	
	
	
2	Centers	for	Disease	Control	and	Prevention.	Sexually	Transmitted	Disease	Surveillance	2017.	Atlanta:	U.S.	Department	of	
Health	and	Human	Services;	2018	 	
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• In	2017,	the	infectious	syphilis	incidence	rate	was	highest	among	individuals	aged	25	to	29	
years,	followed	by	individuals	20	to	24	years,	and	30	to	39	years.	
• In	2017,	the	infectious	syphilis	incidence	rate	among	individuals	aged	25	to	29	years	was	
nearly	triple	the	overall	statewide	incidence	rate	among	all	ages	(47.0	compared	to	15.9	per	
100,000),	and	the	rate	among	individuals	20	to	24	years	and	30	to	39	years	were	
approximately	double	(33.2,	and	31.3,	respectively,	compared	to	15.9	per	100,000).		
	
Additional	information	about	infectious	syphilis	and	other	STDs	is	available	online	at	
www.mass.gov/dph/cdc/std.	
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HIV/AIDS		
	
	
	
• The	number	of	people	known	to	be	living	with	HIV	infection	in	Massachusetts	increased	by	
23%	from	18,201	on	December	31,	2007	to	22,329	on	December	31,	2016.		
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• In	2016,	there	were	641	HIV	infections	diagnosed	and	260	deaths	among	people	reported	
with	HIV	infection	in	Massachusetts.		
• The	number	of	annual	HIV	infection	diagnoses	decreased	by	16%	from	2007	(N=766)	to	
2016	(N=641).	
• During	the	same	time	period,	the	number	of	all-cause	deaths	among	people	reported	with	
HIV	infection	ranged	from	234	(2011)	to	288	(2009).	
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• Of	the	351	cities	and	towns	in	Massachusetts,	196	(56%)	had	at	least	one	reported	HIV	
infection	diagnosis	from	2014	to	2016.	
• Of	those	cities	and	towns	where	HIV	infections	were	diagnosed	within	the	three-year	period	
2014	to	2016,	the	majority	(90%)	had	rates	under	ten	per	100,000	population.		
• Provincetown	was	the	only	locality	with	a	rate	of	over	100	per	100,000	during	this	time	
period.	
• Other	areas	with	higher	average	annual	incidence	rates	were	clustered	in	and	around	major	
cities	such	as	Lawrence	(30.1	per	100,000),	Brockton	(28.1	per	100,000),	Lowell	(25.0	per	
100,000),	Boston	(24.8	per	100,000),	and	Springfield	(24.4	per	100,000).			
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• From	2014	to	2016,	of	the	1,899	HIV	infections	newly	diagnosed	in	Massachusetts,	1,409	
(74%)	were	among	men	and	490	(26%)	were	among	women.			
• From	2014	to	2016,	the	primary	exposure	mode	for	newly	diagnosed	HIV	infection	among	
men	was	male-to-male	sex	(60%)	and	among	women	was	presumed	heterosexual	sex	
(44%).3	A	substantial	proportion	of	diagnoses	among	both	men	and	women	were	reported	
with	No	Identified	Risk	(26%	and	29%,	respectively).	
• The	proportion	of	HIV	infection	diagnoses	with	IDU	exposure	mode	decreased	from	13%	
(N=99/766)	in	2007	to	5%	(N=30/653)	in	2014,	then	increased	to	10%	(N=67/641)	in	2016.		
	
	
	 	
                                                
3	The	category	of	presumed	heterosexual	is	used	exclusively	for	women,	to	define	HIV	exposure	mode	among	
cases	when	sex	with	men	is	the	only	reported	risk	factor	for	HIV	infection.	
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• Since	the	mid-1990’s,	there	has	been	a	dramatic	reduction	in	mother-to-child	transmission	
of	HIV	infection	related	to	high	rates	of	antiretroviral	treatment	of	HIV+	women	and	
promotion	of	HIV	screening	during	pregnancy.		
• From	2007	to	2016,	the	number	of	HIV-infected	newborns	remained	between	zero	and	four	
cases	annually.	There	were	no	cases	identified	in	the	past	two	years.			
Additional	information	about	HIV/AIDS	is	available	online	through	the	MDPH	HIV/AIDS	
Epidemiologic	Profile	at		https://www.mass.gov/lists/hivaids-epidemiologic-profiles.	
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VIRAL	HEPATITIS	–	HEPATITIS	B	
	
	
	
	
• An	average	of	1,861	[range:	1,607	(2013)	–	2,041	(2017)]	confirmed	and	probable	chronic	
hepatitis	B	virus	(HBV)	infection	cases	were	reported	each	year	from	2008	to	2017.	
• In	2017,	551	confirmed	chronic	HBV	infection	cases4	were	reported.	An	additional	1,490	
probable	cases	were	reported	for	a	total	of	2,041	confirmed	and	probable	HBV	cases.	
	
	 	
                                                
4	Case	definitions	and	classifications	can	be	found	in	the	Appendix	beginning	on	page	49	
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• In	2017,	the	age-adjusted	incidence	rate	of	newly	diagnosed	confirmed	and	probable	
chronic	HBV	infection	cases	was	29.4	per	100,000	overall,	33.0	per	100,000	among	men,	
and	26.1	per	100,000	among	women.	
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• While	170	confirmed	and	suspect	acute	HBV	infection	cases	were	reported	in	2017	and	156	
in	2016,	an	average	of	131	[range:	124	(2008)	–	141	(2014)]	confirmed	and	suspect	acute	
HBV	cases	were	reported	each	year	from	2008	to	2015.	
• In	2017,	there	were	52	confirmed	acute	and	118	suspect	acute	HBV	cases	for	a	total	of	170	
acute	cases.		 	
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VIRAL	HEPATITIS	-	HEPATITIS	C	
	
	
	
• The	annual	number	of	newly	diagnosed	confirmed	and	probable	hepatitis	C	cases	reported	
in	Massachusetts	since	2008	was	consistently	high	with	an	average	of	8,200	cases	reported	
each	year.5			
• There	were	4,636	confirmed	and	2,988	probable	hepatitis	C	cases	reported	to	MDPH	in	
2017,	for	a	total	of	7,624.			
	
	
	
	
	
	 	
                                                
5	Please	note,	in	2016,	revised	case	definitions	for	acute	and	chronic	HCV	infection	were	implemented	that	contain	
significant	changes	from	the	case	definitions	for	2008	to	2015.	For	further	information	see	
https://wwwn.cdc.gov/nndss/conditions/	
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• In	2007,	reported	cases	of	hepatitis	C	were	distributed	in	a	curve	with	two	age	peaks,	with	
the	lower	peak	at	age	28	years	and	the	higher	peak	at	age	50	years.		
• In	2017,	the	reported	cases	were	again	distributed	in	a	bi-modal	curve,	but	with	the	higher	
peak	at	age	27	years	and	the	lower	peak	at	age	57	years.	
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• Fifty-eight	percent	of	confirmed	and	probable	hepatitis	C	infection	cases	in	those	less	than	
30	years	of	age	were	men,	and	42%	were	women.	
• The	majority	of	new	hepatitis	C	infections	among	persons	less	than	30	years	of	age	were	
attributable	to	blood	exposure	through	injection	drug	use.	
• Sixty-two	percent	of	confirmed	and	probable	hepatitis	C	infection	cases	in	those	30	years	of	
age	and	older	were	men,	and	38%	were	women.	
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SPECIFIC	POPULATIONS:	ADOLESCENTS	&	YOUNG	ADULTS	
	
	
	
• In	2017,	in	Massachusetts,	62%	of	chlamydia	cases	and	33%	of	gonorrhea	cases	were	
reported	among	adolescents	and	young	adults	aged	15–24	years.		
o Nationally	in	2017,	63%	of	chlamydia	cases	and	45%	of	gonorrhea	cases	were	
reported	among	adolescents	and	young	adults	aged	15–24	years.6			
	 	
                                                
6	Centers	for	Disease	Control	and	Prevention.	Sexually	Transmitted	Disease	Surveillance	2017.	Atlanta:	U.S.	Department	of	
Health	and	Human	Services;	2018	
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• During	2014	to	2016,	15%	of	HIV	infection	diagnoses	were	reported	among	adolescents	and	
young	adults	aged	15–24	years.	
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• The	largest	proportions	of	adolescents	and	young	adults	aged	15–24	years	diagnosed	with	
HIV	infection	were	Hispanic/Latino	(36%)	and	black	NH	(33%).	
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• During	2014	to	2016,	the	primary	exposure	mode	for	HIV	infection	among	adolescents	and	
young	adults	was	male-to-male	sex	(63%),	followed	by	presumed	heterosexual	sex	(8%),	
heterosexual	sex		(7%),	injection	drug	use	(4%),	and	all	other	exposure	modes	(2%).	Sixteen	
percent	of	adolescents	and	young	adults	were	reported	with	no	identified	risk	(NIR).
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• The	age	distribution	of	hepatitis	C	virus	
(HCV)	cases	reported	in	Massachusetts	
changed	between	2002	and	2017	with	a	
significant	increase	in	cases	among	
young	persons	who	inject	drugs.		
• In	2002,	reported	HCV	cases	were	
distributed	in	a	curve	with	one	age	peak	
at	45	years.		
• By	2007,	the	development	of	a	second	
epidemic	among	younger	persons	
became	apparent,	as	reported	cases	
were	distributed	in	a	bi-modal	curve	with	
one	peak	at	28	years	of	age	and	a	second	
peak	at	50	years.	
• In	2017,	HCV	cases	among	young	persons	
who	inject	drugs	outnumbered	newly	
reported	cases	among	the	older	age	
(“baby	boomer”)	cohort.	
• The	proportion	of	cases	among	young	
adults	(aged	15–29	years)	was	higher	in	
2017	(27%,	N=2,009/7,360)	and	2007	
(22%,	N=1,846/8,219)	compared	to	2002	
(10%,	N=999/10,460).	
• The	primary	risk	for	hepatitis	C	infection	
in	younger	adults	is	injection	drug	use.		
While	the	primary	exposure	mode	for	
HIV	infection	in	younger	adults	is	male-
to-male	sex,	recent	increases	in	the	
number	of	HIV	infections	attributed	to	
injection	drug	use	have	been	observed,	
particularly	among	young	adults	(aged	
13–29	years.		
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Reported	Sexual	Behaviors	Among	Massachusetts	High	School	Students,	2009–
2017 
 Percentage	who	reported: 
2009 2011 2013 2015 2017 
 %	(95%	CI) 
%	
(95%	CI) 
%		
(95%	CI) 
%		
(95%	CI) 
%	
(95%	CI) 
Ever	having	sexual	
intercourse 
46.4%		
(42.6–50.2) 
42.0%		
(37.5–46.6) 
38.1%		
(34.3–42.0) 
36.4%		
(32.4–40.6) 
35.3%		
(31.8–39.1) 
Having	sexual	intercourse	
before	age	13 
5.4%		
(4.3–6.8) 
4.2%		
(3.1–5.5) 
3.0%		
(2.4–3.8) 
2.9%		
(2.2–3.8) 
2.4%		
(1.6–3.4) 
Having	had	sexual	
intercourse	with	4+	
partners	during	their	life	 
	
12.9%		
(10.9–15.1) 
	
11.4%		
(9.1–14.2) 
	
9.3%		
(8.0–10.8) 
	
7.9%		
(6.2–10.0) 
	
6.7%		
(5.4–8.2) 
Using	a	condom	at	last	
sexual	intercourse1 
57.5%		
(54.1–60.8) 
57.7%		
(52.8–62.5) 
57.6%		
(52.9–62.2) 
62.5%		
(58.9–65.9) 
57.8%		
(53.1–62.3) 
Drinking	alcohol	or	using	
drugs	before	last	sexual	
intercourse1 
	
23.5%		
(20.0–27.3) 
	
22.7%		
(19.5–26.4) 
	
23.5%		
(19.9–27.5) 
	
21.8%		
(18.1–26.0) 
	
18.2%		
(15.8–21.0) 
Ever	injecting	any	illegal	
drug2 
1.9%		
(1.0–2.6) 
1.8%		
(1.2–2.5) 
1.0%		
(0.5–1.4) 
1.1%	
(0.7–1.6) 
1.0%		
(0.5	–	1.5)	 
n3 2,698 2,726 2,711 3,114 3,275 
1	Among	youth	reporting	sexual	intercourse	in	the	past	three	months	
2	Data	Source	for	ever	injecting	any	illegal	drug	into	your	body	for	2009–2013	is	the	Massachusetts	Youth	Risk	Behavior	Survey,	for	2015–2017	the	
data	source	is	the	Massachusetts	Youth	Health	Survey	(Nationally	the	question	was	removed	from	the	YRBS	after	2013,	after	which	Massachusetts	
added	it	to	the	Youth	Health	Survey)	
3	The	number	of	respondents	(unweighted)	varied	for	each	question	because	participants	may	not	answer	all	questions.	
Data	Source:	Massachusetts	Department	of	Elementary	and	Secondary	Education,	Massachusetts	Youth	Risk	Behavior	Survey	
	
• The	Massachusetts	Youth	Risk	Behavior	Survey	(MYRBS)	is	performed	biennially	among	a	
sample	of	ninth	to	twelfth	grade	students.			
• Three	indicators	of	high-risk	youth	sexual	behavior	(ever	having	sexual	intercourse,	having	
sexual	intercourse	before	age	13	years,	having	had	sexual	intercourse	with	four	or	more	
partners	during	their	life)	reached	their	lowest	levels	in	2017	(35.3%,	2.4%,	and	6.7%,	
respectively).		
• Lifetime	injection	drug	use	remained	at	a	low	of	1%	in	2017.		
• From	2009	to	2017,	there	were	no	significant	changes	in	condom	use,	alcohol	use,	or	drug	
use	before	last	sexual	intercourse.	
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SPECIFIC	POPULATIONS:	WOMEN	AND	INFANTS	
	
	
	
• Unlike	gonorrhea,	chlamydia	infection	in	Massachusetts	is	more	commonly	diagnosed	and	
reported	among	women.	Routine	screening	for	chlamydia	infection	is	recommended	for	
asymptomatic,	sexually	active	women	aged	24	years	and	younger	and	among	older	women	
who	are	at	increased	risk	for	infection	by	the	U.S.	Preventive	Services	Task	Force	(USPSTF).7	
• From	2008	to	2017,	the	number	of	chlamydia	cases	reported	among	women	increased	by	
48%	(from	12,568	to	18,649).	
• The	number	of	chlamydia	cases	reported	among	men	more	than	doubled	from	2008	
(N=4,857)	to	2017	(N=10,467).	Routine	screening	is	not	currently	recommended	by	the	
USPSTF	for	all	sexually	active	men.	
	
	 	
                                                
7	Published	Recommendations.	U.S.	Preventive	Services	Task	Force.	
https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations	
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• In	2017,	64%	of	reported	chlamydia	cases	were	among	women	(N=18,649)	and	36%	were	
among	men	(N=10,467).			
• In	2017,	32%	of	reported	gonorrhea	cases	were	among	women	(N=2,324)	and	68%	were	
among	men	(N=4,951).			
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Chlamydia	and	Gonorrhea	Screening:	
Since	1997,	the	Division	of	STD	Prevention	has	partnered	with	other	agencies	to	reduce	pelvic	
inflammatory	disease,	infertility,	and	other	health	consequences	of	chlamydia	and	gonorrhea	
infection	through	screening	and	treatment	of	women	who	are	at	higher	risk	for	infection.	
• In	2017,	10,089	specimens	collected	from	reproductive	aged	women	(aged	15	to	44	
years)	were	tested	at	the	Massachusetts	State	Public	Health	Laboratory	for	chlamydia	
and	gonorrhea	infection,	with	6.4%	and	2.2%	positivity,	respectively.		
	
• Test	results	from	selected	sites	have	yielded	the	following:				
	
Chlamydia	 &	 Gonorrhea	 Screening	 Projects,	 Percent	 Positive	 for	
Infection	Among	Women	of	Reproductive	Age,	Massachusetts,	2017* 
Site	Type Number	tested Percent	
positive	for	
chlamydia 
Percent	
positive	for	
gonorrhea 
School-Based	Health	Centers 416 9.9% 0.5% 
Correctional	Facilities 1,021 4.7% 5.5% 
Family	Planning	Clinics 346 10.1% 2.0% 
Hospital	Based	Clinic 894 5.7% 2.1% 
Expanded	STD	Screening	Sites* 7,360 6.3% 1.8% 
Data	Source:	MDPH	Bureau	of	Infectious	Disease	and	Laboratory	Sciences	
*Includes	reproductive	age	women	(aged	15	to	44	years),	tested	at	Prevention,	Integrated	Counseling,	Screening,	and	Referral	sites	
under	former	IPP	funding	now	known	as	Safety	Net	Services.	
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Congenital	Syphilis	Prevention:	
	
	
	
• In	2017,	there	were	no	reported	cases	of	congenital	syphilis8	in	Massachusetts.		
• Massachusetts	was	one	of	only	13	states	that	reported	no	congenital	syphilis	cases	in	2017.	
Nationally,	the	congenital	syphilis	rate	increased	from	9.2	cases	per	100,000	live	births	in	
2013	to	23.3	cases	per	100,000	live	births	in	2017.9		
• The	few	cases	of	congenital	syphilis	occurring	in	Massachusetts	in	recent	years	were	born	to	
women	with	little	or	no	prenatal	care,	or	women	who	were	not	known	to	be	at	high	risk	for	
syphilis	infection,	and	therefore	did	not	receive	repeat	syphilis	screening	in	the	third	
trimester	or	at	delivery.	
	
	 	
                                                
8	A	condition	caused	by	infection	in	utero	with	Treponema	pallidum.	A	wide	spectrum	of	severity	exists,	from	
inapparent	infection	to	severe	cases	that	are	clinically	apparent	at	birth.	For	more	information	see	
http://www.cdc.gov/std/stats/congenitalsyphilisdef-rev-jan-2015.pdf	
	
9	Centers	for	Disease	Control	and	Prevention.	Sexually	Transmitted	Disease	Surveillance	2017.	Atlanta:	U.S.	
Department	of	Health	and	Human	Services;	2018.	
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• During	2014	to	2016,	presumed	heterosexual	sex	(44%)	was	the	predominant	exposure	
mode	for	women	diagnosed	with	HIV	infection	in	Massachusetts,	followed	by	heterosexual	
sex	(15%),	injection	drug	use	(11%),	and	other	exposure	modes	(1%).	Twenty-nine	percent	
of	women	were	reported	with	no	identified	risk.	
• Among	women,	the	proportion	of	HIV	infection	diagnoses	with	IDU	exposure	mode	
decreased	from	18%	(N=40/222)	in	2007	to	7%	(N=11/163)	in	2014,	then	increased	to	14%	
(N=24/167)	in	2016.	 	
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• During	2014	to	2016,	50%	of	women	diagnosed	with	HIV	infection	were	born	outside	of	the	
U.S.		Among	men	diagnosed	with	HIV	infection	during	2014	to	2016,	only	31%	were	born	
outside	of	the	U.S.	
• Women	born	outside	the	United	States,	and	recently	diagnosed	with	HIV	infection	in	
Massachusetts,	were	primarily	from	sub-Saharan	Africa	(45%),	the	Caribbean	(37%),	and	
Central	or	South	America	(12%).		
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SPECIFIC	POPULATIONS:	RACIAL/ETHNIC	MINORITIES	
	
	
	
• In	2017,	black	NH	and	Hispanic/Latino	individuals	represented	8%	and	12%	of	the	total	
Massachusetts	population,	and	15%	and	22%	of	infectious	syphilis	cases	(with	known	
race/ethnicity),	respectively.		
• During	2014	to	2016,	black	NH	and	Hispanic/Latino	individuals	represented	31%	and	26%	of	
individuals	diagnosed	with	HIV	infection	in	Massachusetts,	respectively.		
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• In	2017,	the	age-adjusted	infectious	syphilis	incidence	rate	among	both	the	black	NH	
population	(29.6	cases	per	100,000)	and	the	Hispanic/Latino	population	(27.8	cases	per	
100,000)	was	more	than	double	the	rate	among	the	white	NH	population	(11.7	cases	per	
100,000).			
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• In	Massachusetts,	in	2018,	the	age-adjusted	HIV	infection	prevalence	rate	among	the	black	
NH	population	(1,625	per	100,000)	was	11	times	greater,	and	among	the	Hispanic/Latino	
population	(1,262	per	100,000)	was	nine	times	greater	than	among	the	white	NH	
population	(148	per	100,000).		
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• Among	men,	the	largest	proportion	of	newly	diagnosed	HIV	infections	were	among	white	
NH	men,	whereas	among	women	the	majority	of	newly	diagnosed	HIV	infections	were	
among	black	NH	women.	
• With	age-adjusted	annual	average	rates	of	HIV	diagnosis	during	2014	to	2016	of	46.8	and	
26.7	cases	per	100,000	population,	black	NH	and	Hispanic/Latino	individuals	were	
diagnosed	at	rates	10	and	6	times	that	of	white	NH	individuals	(4.6	per	100,000),	
respectively.		
o Among	women,	the	disparity	was	more	pronounced:	the	age-adjusted	annual	
average	rate	of	HIV	diagnosis	during	2014	to	2016	among	black	NH	women	(38.0	per	
100,000)	was	24	times,	and	among	Hispanic/Latina	women	(12.5	per	100,000)	was	
eight	times	that	of	white	NH	women	(1.6	per	100,000).		
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SPECIFIC	POPULATIONS:	MEN	WHO	HAVE	SEX	WITH	MEN	
	
	
	
• Of	the	1,091	infectious	syphilis	cases	reported	in	2017,	850	(78%)	were	among	men	who	
reported	having	sex	with	men	(MSM).	
• The	proportion	of	infectious	syphilis	cases	among	MSM	was	above	65%	from	2008	to	2017.	
• From	2008	to	2017,	the	number	of	reported	infectious	syphilis	cases	among	MSM	more	
than	doubled,	from	301	to	850.	 	
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• The	racial/ethnic	distribution	of	MSM	reported	with	infectious	syphilis	in	2017	was:	
white	NH	(52%),	Hispanic/Latino	(21%),	black	NH	(14%),	Asian/Pacific	Islander	(5%),	and	
other/unknown	race/ethnicity	(8%).		
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• In	2017,	40%	(N=339/850)	of	infectious	syphilis	cases	among	men	reporting	sex	with	men	
were	co-infected	with	HIV.		
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• During	2014	to	2016,	male-to-male	sex	was	the	predominant	exposure	mode	(60%)	for	
men	diagnosed	with	HIV	infection	in	Massachusetts.	Twenty-six	percent	of	men	were	
reported	with	no	identified	risk,	some	of	whom	may	be	MSM.	
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• Among	men,	the	proportion	of	HIV	infection	diagnoses	with	male-to-male	sex	as	the	
reported	mode	of	exposure	remained	between	54%	and	64%	from	2007	to	2016.	During	
the	same	time	period,	the	proportion	reported	with	no	identified	risk	remained	
between	20%	and	26%.	
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Technical	Notes:	Strengths	and	Limitations	of	Data	
	
 	
HIV/AIDS	Case	Data 
	
STD	Case	Data 
	
Viral	Hepatitis	Case	Data 
Description	
 
• Collected	by	MDPH	Bureau	of	Infectious	Disease	and	Laboratory	Sciences	
• Reported	statewide.	
• All	laboratories	and	healthcare	providers	are	required	by	law	to	report.	 
• Includes	individuals	first	
diagnosed	with	HIV	
infection	in	MA. 
• Includes	individuals	first	
reported	as	living	in	MA. 
• Includes	individuals	first	
reported	as	living	in	MA. 
Strengths • Completeness	of	
race/ethnicity	data	is	
high.	
• All	clinical	laboratories	in	
MA	report	electronically	
resulting	in	more	
complete	and	timely	
reporting	of	disease.	
• Data	are	estimated	to	be	
99%	complete. 
• All	clinical	laboratories	in	
MA	report	electronically	
resulting	in	more	
complete	and	timely	
reporting	of	disease.	
• Most	infectious	syphilis	
cases	agree	to	interview,	
resulting	in	reasonably	
complete	race/ethnicity	
and	sex	of	sex	partner	
data. 
• All	clinical	laboratories	in	
MA	report	electronically	
resulting	in	more	
complete	and	timely	
reporting	of	disease. 
Limitations • Due	to	follow	up	
conducted	to	verify	
accurate	date	of	
diagnosis,	annual	
incidence	data	are	
released	a	year	after	the	
close	of	the	year.	For	
example,	2017	HIV	
diagnoses	through	
December	31,	2017	will	
be	released	on	January	1,	
2019. 
• Race/ethnicity	data	are	
incomplete	for	gonorrhea	
and	chlamydia	cases.	
• Sex	of	sex	partner	is	not	
routinely	collected	for	
gonorrhea	and	chlamydia	
cases.	
• Bias	is	introduced	for	
some	STDs,	such	as	
chlamydia	infection,	
where	screening	of	
asymptomatic	persons	
occurs	more	frequently	
among	women	than	
among	men. 
• Race/ethnicity	data	
are	incomplete.	
• Risk	history	data	are	
not	collected	on	
chronic	HBV	cases. 
Massachusetts	Youth	Risk	Behavior	Survey	 
Description The	Massachusetts	Youth	Risk	Behavior	Survey	(MYRBS)	is	conducted	every	two	years	
through	a	collaborative	effort	between	the	Massachusetts	Department	of	Elementary	and	
Secondary	Education	(ESE)	and	Department	of	Public	Health	(DPH)	to	monitor	health	
indicators,	behaviors,	and	risk	factors	contributing	to	the	leading	causes	of	morbidity,	
mortality,	and	social	and	academic	problems	among	adolescents.	 
Strengths A	two-stage	sampling	method	is	used	to	produce	representative	samples	of	students	in	
grades	9	–	12.	Response	rates	are	high.	 
Limitations All	data	collected	for	the	MYRBS	and	the	MYHS	are	based	on	self-report	from	students.	Self-
reported	data	may	be	subject	to	error	for	several	reasons,	including	inaccurate	recall	of	
events.	
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Interpreting	HIV/AIDS,	STD,	and	Viral	Hepatitis	Data	
Hepatitis	B	surveillance	data	are	current	as	of	November	8,	2018,	hepatitis	C	data	are	as	of	
August	17,	2018,	HIV/AIDS	data	are	as	of	January	1,	2018	and	STD	data	are	as	of	December	3,	
2018.	All	data	are	subject	to	change.	
I.		HIV/AIDS	Exposure	Mode	Definitions	
The	HIV/AIDS	exposure	mode	indicates	the	most	probable	risk	behavior	associated	with	HIV	
infection.		Assignment	of	exposure	mode	is	done	in	accordance	with	Centers	for	Disease	Control	
and	Prevention	(CDC)	guidelines	when	multiple	exposure	modes	are	reported.		Following	is	a	
description	of	the	exposure	mode	categories:	
• MSM	(Male	to	Male	Sex):		Includes	males	who	report	sexual	contact	with	other	
males,	and	males	who	report	sexual	contact	with	both	males	and	females.	Please	note	the	
acronym	MSM	is	also	used	to	refer	to	“men	who	have	sex	with	men”.	
• IDU	(Injection	Drug	Use):		Cases	among	persons	who	report	injection	drug	use.	
• MSM/IDU:		Cases	among	males	who	report	both	injection	drug	use	and	sexual	contact	
with	other	males.	
• Heterosexual	Sex:		Cases	among	persons	who	report	specific	heterosexual	sex	with	a	
person			with,	or	at	increased	risk	for,	HIV	infection	(e.g.	an	injection	drug	user).		The	sub-
categories	for	this	mode	of	transmission	are	listed	below.	
o Heterosexual	Sex	w/	an	Injection	Drug	User	
o Heterosexual	Sex	w/	a	person	w/	HIV	infection	or	AIDS	
o Heterosexual	Sex	w/	Bisexual	male	
o Other	Heterosexual	Sex:		Includes	all	other	sub-categories	of	risk,	such	as	heterosexual	
contact	with	a	person	infected	through	a	blood	transfusion.	
• Presumed	Heterosexual:		Cases	among	females	who	report	heterosexual	sex	but	do	
not	report	any	other	personal	risk	or	any	knowledge	of	specific	risk	among	their	male	sex	
partners.		As	of	January	1,	2011,	males	who	were	previously	grouped	in	this	
category	are	categorized	as	No	Identified	Risk.		Presumed	heterosexual	is	an	exposure	
mode	category	used	by	the	Massachusetts	HIV/AIDS	Surveillance	Program.		The	CDC	categorizes	
these	cases	as	No	Identified	Risk.	
• Pediatric:		Infection	before	the	age	of	13	years,	including	mother	to	child	transmission	
through	pregnancy,	childbirth	or	breastfeeding	and	blood	transfusions	to	children.	
• NIR	(No	Identified	Risk):		Cases	among	persons	with	no	reported	history	of	exposure	to	
HIV	through	any	of	the	listed	exposure	categories.		Follow-up	is	conducted	to	determine	risk	for	
those	cases	that	are	initially	reported	without	a	risk	identified.		Includes	cases	among	males	
who	were	previously	categorized	in	Massachusetts	as	Presumed	Heterosexual.	
	
II.		References	to	Newly	Diagnosed	HIV	Infections	
Due	to	the	extensive	follow	up	required	to	verify	accurate	date	of	diagnosis,	all	HIV/AIDS	data	
reflect	HIV	infections	diagnosed	through	2016.		Newly	diagnosed	HIV	infections/cases	include	
all	persons	diagnosed	with	HIV	from	2014	to	2016,	including	those	who	were	concurrently	or	
subsequently	diagnosed	with	AIDS.	All	HIV	data	are	presented	by	the	year	of	diagnosis,	not	the	
year	of	report.	
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III.		Race/Ethnicity	of	STD	and	HIV/AIDS	Cases	
Race/ethnicity	references	to	white	residents	and	black	residents	represent	persons	who	are	white	
NH	and	black	NH,	respectively.		All	references	to	Hispanic/Latino	for	race/ethnicity	represent	
persons	of	Hispanic/Latino	heritage	regardless	of	race.		
IV.		STD	Case	Reports	and	Analyses	
All	information	on	STD	cases	reflect	year	of	report	and	all	incidence	calculations	are	age-
adjusted	using	the	2000	US	standard	population.	The	source	of	denominators	for	calculating	
rate	trends	was:	US	Census	Bureau,	Population	Estimates	Program	in	collaboration	with	
National	Center	for	Health	Statistics,	Revised	2000–2009	Bridged-Race	Intercensal	Population	
Estimates	(2008–2009)	and	Vintage	2017	Bridged-Race	Postcensal	Estimates	(2010–2017),	
Release	dates:	October	2012	and	June	2018,	respectively,	available	at:	
https://www.cdc.gov/nchs/nvss/bridged_race.htm.The	source	of	denominators	for	calculating	rate	
maps	was	the	2010	US	Census,	which	are	the	most	up-to-date	information	available	on	the	
number	of	persons	by	age,	race,	and	sex	at	the	sub-state	level.		
	
The	distribution	of	STD	cases	in	incidence	rate	calculations	with	unknown	values	for	sex	at	birth,	
race/ethnicity	and	age	has	changed	compared	to	reports	prior	to	2016.		When	less	than	30%	of	
cases	have	unknown	values,	they	are	redistributed	proportionally	based	on	the	distribution	of	
cases	with	known	values.	When	the	proportion	of	cases	with	unknown	values	is	greater	than	or	
equal	to	30%,	incidence	rates	are	not	presented	by	that	variable.	For	instance,	race/ethnicity	is	
unknown	for	44%	of	confirmed	chlamydia	cases	and	31%	of	confirmed	gonorrhea	cases	
reported	from	2008	to	2017.	Therefore,	the	age-adjusted	incidence	rates	of	confirmed	
chlamydia	and	gonorrhea	cases	per	100,000	population	by	race/ethnicity	are	not	presented	in	
this	report.	
	
V.	Cell	suppression	methodology:	
Values	less	than	five	are	suppressed	for	denominator	populations	less	than	50,000	or	for	
unknown	values.	Additional	values	may	be	suppressed	to	prevent	back	calculation.	
	
VI.	Explanation	of	age	adjusted	rates:	
	
A	“rate”	of	a	disease	per	100,000	population	is	a	useful	way	to	compare	groups	with	
substantially	different	population	sizes	rather	than	relying	on	the	raw	number	of	cases.			
However,	sometimes,	in	addition	to	the	population	size	being	different,	the	age	composition	of	
the	populations	is	different.		In	Massachusetts,	black	(non-Hispanic)	and	Hispanic/Latino	
populations	are	generally	younger	than	white	(non-Hispanic).	The	median	age	of	black	(non-
Hispanic)	individuals	(29.7	years)	and	Hispanic/Latino	individuals	(24.5	years)	is	younger	than	
that	of	white	(non-Hispanic)	individuals	(38.8	years).	Therefore,	it	is	necessary	to	age-adjust	the	
incidence	and	prevalence	rates	to	get	a	true	comparison	of	the	impact	of	the	disease	across	
racial/ethnic	groups	without	an	effect	from	the	differences	in	age	composition.		Age-
adjustment	of	rates	minimizes	the	distortion	created	by	differences	in	age	composition.			
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Age-adjusted	rates	are	calculated	by	weighting	the	age-specific	rates	for	a	given	population	by	
the	age	distribution	of	a	standard	population.	The	weighted	age-specific	rates	are	then	added	
to	produce	the	adjusted	rate	for	all	ages	combined.	(See	example	1.B	below).	
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Example	1.B:	Calculation	of	age-adjusted	HIV/AIDS	prevalence	rate	for	white	(non-Hispanic)	
individuals,	Massachusetts	(147.7	per	100,000)	
	
A B C D E 
Age	group	(in	
years) 
#	of	prevalent	
HIV/AIDS	cases 
Population	
(2010) 
2000	US	
standard	
population	
weight 
Age-adjusted	rate	
((B÷C×D)×100,000)) 
<1 0 				48,010	 0.013818 0.00 
1–4	 0 		200,452	 0.055317 0.00 
5–14	 3 		571,967	 0.145565 0.08 
15–24	 52 		677,899	 0.138646 1.06 
25–34	 674 		603,245	 0.135573 15.15 
35–44	 1,082 		676,064	 0.162613 26.03 
45–54	 2,680 		841,315	 0.134834 42.95 
55–64	 3,318 		697,852	 0.087247 41.48 
65–74	 1,094 		403,518	 0.066037 17.90 
75–84	 183 		275,380	 0.044842 2.82 
85+	years 17 		136,931	 0.015508 0.19 
Total 9,103 5,132,633 1.000000 147.7	
	 	
2017	Integrated	HIV/AIDS,	STD,	and	Viral	Hepatitis	Surveillance	Report	
Massachusetts	Department	of	Public	Health	
	
	 	 -	51	-	
HIV/AIDS,	STD,	and	Viral	Hepatitis	Case	Classifications	(in	the	time	period	of	the	
data	in	this	report)	
HIV	INFECTION	
	
Clinical	description:	HIV	(human	immunodeficiency	virus)	is	a	retrovirus	with	two	serologically	
and	geographically	distinct	species:	HIV-1	and	HIV-2.	It	is	spread	via	person-to-person	
transmission	through:	sexual	contact,	the	use	of	HIV-contaminated	needles	and	syringes,	
vertical	transmission	from	mother	to	infant,	or	the	transfusion	of	contaminated	blood	or	its	
components.	HIV	attacks	the	body’s	immune	system,	making	the	person	more	likely	to	get	
infections	or	infection-related	cancers.	These	opportunistic	infections	or	cancers	take	
advantage	of	the	weakened	immune	system	and	signal	that	the	person	has	AIDS	(acquired	
immunodeficiency	syndrome),	the	advanced	stage	of	HIV	infection.	
	
Case	Classification	
Confirmed:	Positive	HIV-1,	Positive	HIV-2,	or	Positive	(Undifferentiated)	HIV	result	from	a	
differentiating	immunoassay,	Western	Blot,	IFA,	or	culture;	Positive/Detected	Qualitative	HIV	
NAT	(DNA	or	RNA);	Quantitative	HIV	NAT	(detectable	viral	load	assay)	or	physician	verified	
diagnosis.	
	
	
Sexually	transmitted	diseases	(STD)	
Chlamydia	trachomatis	Infection	(Effective	1/10)	
	
Clinical	description	
Infection	with	Chlamydia	trachomatis	may	result	in	urethritis,	epididymitis,	cervicitis,	acute	
salpingitis,	or	other	syndromes	when	sexually	transmitted;	however,	the	infection	is	often	
asymptomatic	in	women.	Perinatal	infections	may	result	in	inclusion	conjunctivitis	and	
pneumonia	in	newborns.	Other	syndromes	caused	by	C.	trachomatis	include	lymphogranuloma	
venereum	(see	Lymphogranuloma	Venereum)	and	trachoma.	
Laboratory	criteria	for	diagnosis	
• Isolation	of	C.	trachomatis	by	culture	or	
• Demonstration	of	C.	trachomatis	in	a	clinical	specimen	by	detection	of	antigen	or	nucleic	
acid	
Case	classification	
Confirmed:	a	case	that	is	laboratory	confirmed.	
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Gonorrhea	(Effective	1/14)	
	
Clinical	description	
A	sexually	transmitted	infection	commonly	manifested	by	urethritis,	cervicitis,	proctitis,	
salpingitis,	or	pharyngitis.	Infection	may	be	asymptomatic.	
Laboratory	criteria	for	diagnosis	
• Observation	of	gram-negative	intracellular	diplococci	in	a	urethral	smear	obtained	from	
a	male	or	an	endocervical	smear	obtained	from	a	female,	or	
• Isolation	of	typical	gram-negative,	oxidase-positive	diplococci	by	culture	
(presumptive	Neisseria	gonorrhoeae)	from	a	clinical	specimen,	or	
• Demonstration	of	N.	gonorrhoeae	in	a	clinical	specimen	by	detection	of	antigen	or	
nucleic	acid	
Case	classification	
Probable:	demonstration	of	gram-negative	intracellular	diplococci	in	a	urethral	smear	obtained	
from	a	male	or	an	endocervical	smear	obtained	from	a	female.	
Confirmed:	a	person	with	laboratory	isolation	of	typical	gram-negative,	oxidase-positive	
diplococci	by	culture	(presumptive	N.	gonorrhoeae)	from	a	clinical	specimen,	or	demonstration	
of	N.	gonorrhoeae	in	a	clinical	specimen	by	detection	of	antigen	or	detection	of	nucleic	acid	via	
nucleic	acid	amplification	(e.g.,	polymerase	chain	reaction	[PCR])	or	hybridization	with	a	nucleic	
acid	probe.	
Syphilis	(Effective	1/14)	
	
Syphilis	is	a	complex	sexually	transmitted	disease	that	has	a	highly	variable	clinical	course.	
Adherence	to	the	following	surveillance	case	definitions	will	facilitate	understanding	the	
epidemiology	of	this	disease	across	the	US.	
Syphilis,	primary	(Effective	1/14)	
Clinical	description	
A	stage	of	infection	with	Treponema	pallidum	characterized	by	one	or	more	ulcerative	lesions	
(e.g.	chancre),	which	might	differ	considerably	in	clinical	appearance.	
Laboratory	criteria	for	diagnosis	
Demonstration	of	T.	pallidum	in	clinical	specimens	by	darkfield	microscopy,	or	by	PCR	or	
equivalent	direct	molecular	methods.	
Case	classification	
Probable:	a	case	that	meets	the	clinical	description	of	primary	syphilis	with	a	reactive	serologic	
test	(nontreponemal:	Venereal	Disease	Research	Laboratory	[VDRL],	rapid	plasma	reagin	[RPR],	
or	equivalent	serologic	methods;	treponemal:	fluorescent	treponemal	antibody	absorbed	[FTA-
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ABS],	T.	pallidum	particle	agglutination	[TP-PA],	enzyme	immunoassay	[EIA],	
chemiluminescence	immunoassay	[CIA],	or	equivalent	serologic	methods).	These	treponemal	
tests	supersede	older	testing	technologies,	including	microhemagglutination	assay	for	antibody	
to	T.	pallidum	[MHA-TP].	
Confirmed:	a	case	that	meets	the	clinical	description	of	primary	syphilis	that	is	laboratory	
confirmed.	
Syphilis,	secondary	(Effective	1/14)	
Clinical	description	
A	stage	of	infection	caused	by	T.	pallidum	characterized	by	localized	or	diffuse	mucocutaneous	
lesions	(e.g.,	rash	–	such	as	non-pruritic	macular,	maculopapular,	popular,	or	pustular	lesions),	
often	with	generalized	lymphadenopathy.	Other	symptoms	can	include	mucous	patches,	
condyloma	lata,	and	alopecia.	The	primary	ulcerative	lesion	may	still	be	present.	Because	of	the	
wide	array	of	symptoms	possibly	indicating	secondary	syphilis,	serologic	tests	for	syphilis	and	a	
thorough	sexual	history	and	physical	examination	are	crucial	to	determining	if	a	case	should	be	
classified	as	secondary	syphilis.	
Laboratory	criteria	for	diagnosis	
Demonstration	of	T.	pallidum	in	clinical	specimens	by	darkfield	microscopy,	or	by	PCR	or	
equivalent	direct	molecular	methods.	
Case	classification	
Probable:	a	case	that	meets	the	clinical	description	of	secondary	syphilis	with	a	nontreponemal	
(VDRL,	RPR,	or	equivalent	serologic	methods)	titer	≥4	and	a	reactive	treponemal	test	(FTA-ABS,	
TP-PA,	EIA,	CIA,	or	equivalent	serologic	methods).	
Confirmed:	a	case	that	meets	the	clinical	description	of	secondary	syphilis	(with	at	least	one	
sign	or	symptom)	that	is	laboratory	confirmed.	
Syphilis,	early	latent	(Effective	1/14)	
Clinical	description	
A	subcategory	of	latent	syphilis	(a	stage	of	infection	caused	by	T.	pallidum	in	which	organisms	
persist	in	the	body	of	the	infected	person	without	causing	symptoms	or	signs)	when	initial	
infection	has	occurred	within	the	previous	12	months.	
Case	classification	
Probable:	A	person	with	no	clinical	signs	or	symptoms	of	syphilis	who	has	one	of	the	following:	
• No	past	diagnosis	of	syphilis,	and	a	reactive	nontreponemal	test	(e.g.,	VDRL,	RPR,	or	
equivalent	serologic	methods),	and	a	reactive	treponemal	test	(e.g.,	FTA-ABS,	TP-PA,	
EIA,	CIA,	or	equivalent	serologic	methods),	or	
• A	current	nontreponemal	test	titer	demonstrating	fourfold	or	greater	increase	from	the	
last	nontreponemal	test	titer	
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AND	evidence	of	having	acquired	the	infection	within	the	previous	12	months	based	on	one	or	
more	of	the	following	criteria:	
• Documented	seroconversion	or	fourfold	or	greater	increase	in	titer	of	a	nontreponemal	
test	during	the	previous	12	months	
• Documented	seroconversion	of	a	treponemal	test	during	the	previous	12	months	
• A	history	of	symptoms	consistent	with	primary	or	secondary	syphilis	during	the	previous	
12	months	
• A	history	of	sexual	exposure	to	a	partner	within	the	previous	12	months	who	had	
primary,	secondary,	or	early	latent	syphilis	(documented	independently	as	duration	<12	
months)	
• Only	sexual	contact	was	within	the	last	12	months	(sexual	debut).	
There	is	no	confirmed	case	classification	for	early	latent	syphilis.	
Syphilis,	late	latent	(Effective	1/14)	
Clinical	description	
A	subcategory	of	latent	syphilis	(a	stage	of	infection	caused	by	T.	pallidum	in	which	organisms	
persist	in	the	body	of	the	infected	person	without	causing	symptoms	or	signs)	when	initial	
infection	has	occurred	>12	months	previously.	
Case	classification	
Probable:	a	person	with	no	clinical	signs	or	symptoms	of	syphilis	who	has	one	of	the	following:	
• No	past	diagnosis	of	syphilis,	and	a	reactive	nontreponemal	test	(e.g.,	VDRL,	RPR,	or	
equivalent	serologic	methods),	and	a	reactive	treponemal	test	(e.g.,	FTA-ABS,	TP-PA,	
EIA,	CIA,	or	equivalent	serologic	methods),	or	
• A	past	history	of	syphilis	therapy	and	a	current	nontreponemal	test	titer	demonstrating	
fourfold	or	greater	increase	from	the	last	nontreponemal	test	titer.	
AND	who	has	no	evidence	of	having	acquired	the	disease	within	the	preceding	12	months	(see	
Syphilis,	early	latent).	
There	is	no	confirmed	case	classification	for	late	latent	syphilis.	
Syphilis,	Congenital	(Effective	1/15)	
Clinical	description	
A	condition	caused	by	infection	in	utero	with	T.	pallidum.	A	wide	spectrum	of	severity	exists,	
from	inapparent	infection	to	severe	cases	that	are	clinically	apparent	at	birth.	An	infant	or	child	
(aged	less	than	2	years)	may	have	signs	such	as	hepatosplenomegaly,	rash,	condyloma	lata,	
snuffles,	jaundice	(nonviral	hepatitis),	pseudoparalysis,	anemia,	or	edema	(nephrotic	syndrome	
and/or	malnutrition).	An	older	child	may	have	stigmata	(e.g.,	interstitial	keratitis,	nerve	
deafness,	anterior	bowing	of	shins,	frontal	bossing,	mulberry	molars,	Hutchinson	teeth,	saddle	
nose,	rhagades,	or	Clutton	joints).	
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Laboratory	criteria	for	diagnosis	
• Demonstration	of	T.	pallidum	by	darkfield	microscopy	of	lesions,	body	fluids,	or	
neonatal	nasal	discharge,	or	
• PCR	or	other	equivalent	direct	molecular	methods	of	lesions,	placenta,	umbilical	cord,	or	
autopsy	material,	or	
• Immunohistochemistry	(IHC),	or	special	stains	(e.g.,	silver	staining)	of	specimens	from	
lesions,	neonatal	nasal	discharge,	placenta,	umbilical	cord,	or	autopsy	material.	
Case	classification	
Probable:	a	condition	affecting	an	infant	whose	mother	had	untreated	or	inadequately	treated*	
syphilis	at	delivery,	regardless	of	signs	in	the	infant,	or	an	infant	or	child	who	has	a	reactive	non-
treponemal	test	for	syphilis	(VDRL,	RPR,	or	equivalent	serologic	methods)	AND	any	one	of	the	
following:	
• Any	evidence	of	congenital	syphilis	on	physical	examination	(see	Clinical	description)	
• Any	evidence	of	congenital	syphilis	on	radiographs	of	long	bones	
• A	reactive	CSF	VDRL	test	
• In	a	nontraumatic	lumbar	puncture,	an	elevated	CSF	leukocyte	(white	blood	cell	[WBC])	
count	or	protein	(without	other	cause):	
*	Adequate	treatment	is	defined	as	completion	of	a	penicillin-based	regimen,	in	accordance	
with	CDC	treatment	guidelines,	appropriate	for	stage	of	infection,	initiated	30	or	more	days	
before	delivery.	
Suggested	parameters	for	abnormal	CSF	WBC	and	protein	values:	
• During	the	first	30	days	of	life,	a	CSF	WBC	count	of	>15	WBC/mm3	or	a	CSF	protein	>120	
mg/dL.	
• After	the	first	30	days	of	life,	a	CSF	WBC	count	of	>5	WBC	mm3	or	a	CSF	protein	>40	
mg/dL,	regardless	of	CSF	serology.	
• The	treating	clinician	should	be	consulted	to	interpret	the	CSF	values	for	the	specific	
patient.	
Confirmed:	a	case	that	is	laboratory	confirmed.	
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Viral	Hepatitis	
	
Hepatitis	is	inflammation	of	the	liver.	It	can	impair	vital	liver	functions	such	as	processing	
nutrients,	filtering	the	blood	and	fighting	infection.	Viral	hepatitis	is	inflammation	of	the	liver	
caused	by	infection	with	a	virus.	In	Massachusetts,	the	most	common	types	of	viral	hepatitis	are	
hepatitis	A,	hepatitis	B	and	hepatitis	C.	Hepatitis	can	also	result	from	heavy	alcohol	use,	toxins,	
some	medications,	and	certain	medical	conditions.		
	
Chronic	HBV	
Confirmed:	
	
IgM	antibodies	to	hepatitis	B	core	antigen	(IgM	anti-HBc)	negative		
	
AND		
	
A	positive	result	on	one	of	the	following	tests:	hepatitis	B	surface	antigen	(HBsAg),	
hepatitis	B	e	antigen	(HBeAg),	or	nucleic	acid	test	for	hepatitis	B	virus	DNA	(including	
qualitative,	quantitative	and	genotype	testing),		
	
OR	
	
HBsAg	positive	or	nucleic	acid	test	for	hepatitis	B	virus	DNA	(including	qualitative,	
quantitative	and	genotype	testing),	or	HBeAg	positive	two	times	at	least	6	months	apart	
(Any	combination	of	these	tests	performed	6	months	apart	is	acceptable.)	
	
Probable:	
A	case	with	a	single	HBsAg	positive	or	HBV	DNA	positive	(including	qualitative,	quantitative	and	
genotype	testing),	or	HBeAg	positive	lab	result	when	no	IgM	anti-HBc	results	are	available	
	
Acute	HBV	infection	
Clinical	Presentation:	 An	acute	illness	with	a	discrete	onset	of	symptoms	consistent	with	
acute	viral	hepatitis	(e.g.,	fever,	headache,	malaise,	anorexia,	nausea,	vomiting,	diarrhea,	and	
abdominal	pain)	and	either	a)	jaundice	or	b)	elevated	serum	alanine	aminotransferase	levels	>	
100	IU/L	
	
Confirmed:	
Clinically	compatible	case*	not	known	to	have	chronic	hepatitis	B	and	
HBsAg	positive		
	
AND	
	
IgM	antibody	to	hepatitis	B	core	antigen	(IgM	anti–	HBc)	positive,	if	done	*		
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A	documented	negative	hepatitis	B	surface	antigen	(HBsAg)	laboratory	test	result	within	6	
months	prior	to	a	positive	test	(either	HBsAg,	Hepatitis	B	“e”	antigen	(HBeAg),	or	hepatitis	B	
virus	nucleic	acid	testing	(HBV	NAT)	including	genotype)	result	does	NOT	require	an	acute	
clinical	presentation	to	meet	the	surveillance	case	definition.	
	
Suspect:	
Positive	IgM	antibody	to	hepatitis	B	core	antigen	(IgM	anti-HBc)	that	does	not	meet	the	clinical	
definition	
	
Note	that	the	year	into	which	a	case	is	categorized	is	based	upon	the	case’s	“Event	Date”,	which	
is	assigned	by	the	following	case	characteristics,	in	decreasing	order	of	specificity,	dependent	on	
availability	of	information:	symptom	onset	date,	specimen	collection	date,	diagnosis	date,	or	
case	report	date	
	
Past	or	Present	HCV	 Infection	Newly	Reported	to	MDPH	
Confirmed:	
One	or	more	of	the	following	criteria	(except	among	persons	less	than	18	months	of	age,	for	
whom	only	criteria	3	would	meet	the	case	classification	criteria):	
	
Antibodies	to	hepatitis	C	virus	(anti-HCV)	screening-test-positive	with	a	 signal	 to	cut-off	 ratio	
predictive	of	a	 true	positive	as	determined	for	the	particular	assay	as	defined	by	CDC	
	
OR	
	
Hepatitis	C	Virus	Recombinant	Immunoblot	Assay	(HCV	RIBA)	positive	
	
OR	
	
Nucleic	Acid	Test	(NAT)	for	HCV	RNA	positive	(including	qualitative,	quantitative,	or	genotype)	
	
Probable:	
	
Rapid	HCV	antibody	positive	test	
	
OR	
	
Anti-HCV	screening-test-positive	that	has	not	been	verified	by	a	more	specif ic 	assay	or	has	
unknown	signal	 to	cut-off	ratio	(regardless	of	ALT	results	and	acute	hepatitis	C	status)	
	
Acute	HCV	Infection	
Confirmed:	
Clinically	 compatible	 presentation*	 not	 known	 to	 have	 chronic	HCV	with	1	or	more	of	the	
following:	
	
Anti-HCV	screening-test-positive	with	a	signal	to	cut-off	ratio	predictive	of	a	 true	positive	as	
2017	Integrated	HIV/AIDS,	STD,	and	Viral	Hepatitis	Surveillance	Report	
Massachusetts	Department	of	Public	Health	
	
	 	 -	58	-	
determined	 for	 the	particular	assay	as	defined	by	CDC	
	
OR	
	
HCV	RIBA	positive	
	
OR	
	
NAT	for	HCV	RNA	positive	(including	qualitative,	quantitative,	or	genotype)	
	
AND	
	if	done	meets	the	following	two	criteria†:	
	
IgM	anti-HAV	negative	AND	
IgM	anti-HBV	negative	
	
*	 -	A	documented	negative	HCV	antibody	 laboratory	 result	 followed	within	6	months	by	
a	positive	test	result	(as	described	above)	does	NOT	require	an	acute	clinical	
presentation	to	meet	the	confirmed	case	definition	
	
†	 -	 From	 2007–2013,	 cases	 meeting	 the	 acute	 case	 definition	 but	missing	a	negative	
HAV	&	HBV	result	were	classified	as	Suspect.	The	case	definition	change	in	2013	
eliminated	this	requirement.	
	
Suspect:	
	
A	documented	negative	HCV	antibody	 laboratory	test	result	followed	 within	 6-12	
months	 by	 a	 positive	 test	 result	 (as	described			 above)	does	NOT	require	an	acute	
clinical	presentation	to	meet	the	suspect	case	definition.	
	
Low	 level	 viremia	 (<100,000	 IU/mL)	not	 known	 to	have	 chronic	HCV	
	
Note	 that	 the	 year	 into	which	 a	 case	 is	 categorized	 is	 based	 upon	 the	case’s	 “Event	
Date”,	 which	 is	assigned	by	the	 following	 case	characteristics,	 in	decreasing	order	of	
specificity,	dependent	on	availability	of	information:	symptom	onset	date,	specimen	
collection	date,	diagnosis	date,	or	case	report	date.	
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HIV/AIDS,	STD	and	Viral	Hepatitis	Program	Staff	Contact	Information	
	
Topic Contact E-Mail Phone	
 
Division	of	STD	Prevention	&	HIV/AIDS	Surveillance,	and	
Ratelle	STD/HIV	Prevention	Training	Center 
Policy	Development	and	
Administration 
Kathleen	Roosevelt	(Director,	STD	
Prevention	Division) 
Kathleen.Roosevelt@state.ma.us 617-983-6941 
Sylvie	Ratelle	STD/HIV	
Prevention	Training	Center 
Katherine	Hsu	(Medical	Director)	
Janine	Dyer	(Deputy	Director) 
Katherine.Hsu@state.ma.us	
Janine.Dyer@state.ma.us 
617-983-6948	
617-983-6964 
STD/HIV/AIDS	Surveillance	
and	Epidemiology 
Betsey	John	(Director,	HIV/AIDS	and	STD	
Surveillance)	
 
Betsey.John@state.ma.us	
	
 
617-983-6570	
 
STD	Clinical	Services	 Katherine	Hsu	(Medical	Director)	
Lila	Coverstone	(Public	Health	Nurse) 
Katherine.Hsu@state.ma.us	
Lila.Coverstone@state.ma.us		 
617-983-6948	
617-983-6959 
STD	Disease	Intervention	
Field	Services	and		
STD	Partner	Notification 
David	Goudreau	
(Field	Operations	Manager)	
Christopher	Borger	
(Field	Operations	Manager)	
Brenda	Hernandez	
(Field	Operations	Manager)	
Courtney	Breen	
(Field	Operations	Manager)	
David.Goudreau@state.ma.us	
	
Chris.Borger@state.ma.us			
	
Brenda.Hernandez@state.ma.us	
	
Courtney.Breen@state.ma.us	
	
978-851-7321	
x	4064	
617-983-6930	
	
617-983-6943	
	
617-983-6955	
STD	Health	Education,	
Training,	and	Prevention	
Victor	Ramirez		
(Special	Projects	Coordinator)	
Victor.Ramirez@state.ma.us	
	
	
617-983-6567	
	
	
Office	of	HIV/AIDS 
HIV/AIDS	Resource	
Allocation,	Policy,	and		
Programs	 
Dawn	Fukuda	(Director,	Office	of	
HIV/AIDS)	
 
Dawn.Fukuda@state.ma.us	
	
 
617-624-5303	
	
 
Health	Promotion	and	
Disease	Prevention	
Services	
 
Linda	Goldman,	(Director	of	Health	
Promotion	and	Disease	Prevention)		
 
Linda.Goldman@state.ma.us	
 
617-624-5347	
 
Behavioral	Health	and	
Community	Engagement		
 
Barry	Callis		
(Director	of	Behavioral	Health	and	
Infectious	Disease	Prevention	
 
Barry.Callis@state.ma.us	
 
617-624-5316	
 
Viral	Hepatitis	Program 
Viral	Hepatitis	Surveillance	
and	Epidemiology	
Lindsay	Bouton	(Programmatic	
epidemiologist	for	hepatitis	A	and	B	
Molly	Crockett	(Surveillance	
epidemiologist	for	hepatitis	A	and	B)	
Anthony	Osinski	(Programmatic	
epidemiologist	for	hepatitis	C)	
Susan	Soliva	(Surveillance	epidemiologist	
for	hepatitis	C)	
	
Lindsay.Bouton@state.ma.us	
	
Molly.Crockett@state.ma.us		
	
Anthony.Osinski@state.ma.us	
	
Susan.Soliva@state.ma.us	
	
617-983-6800	
	
617-983-6801	
	
617-983-6800	
	
617-983-6801	
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HIV/AIDS,	STD,	and	Viral	Hepatitis	Resources	
	
Training	
Professional	training	to	community	based	organizations,	local	public	health	departments,	and	medical	providers	
can	be	requested	and	is	free	of	charge.		
Type	of	Training Contact	Information	and	Website 
STD	Education,	STD	Partner	Notification,	and		
STD	Reporting	 
617-983-6940	
www.mass.gov/dph/cdc/std 
HIV/AIDS	Reporting	and	Surveillance	Projects 617-983-6560	www.mass.gov/dph/cdc/aids 
HIV/AIDS	Provider	Trainings 617-624-5338		www.mass.gov/dph/aids	 
Viral	Hepatitis	Education 
617-983-6800	
https://www.mass.gov/lists/hepatitis-b-educational-materials-
and-other-resources 
https://www.mass.gov/lists/hepatitis-c-educational-materials-
and-other-resources 
STD	Diagnosis,	Treatment,	and	Management 617-983-6945	www.RatellePTC.org	
Material	and	Clinical	Toolkits		
Health	education	materials	and	clinical	toolkits	can	be	requested	free	of	charge.		
Type	of	Material Contact	Information	and	Website 
STD,	HIV,	Viral	Hepatitis	Fact	Sheets	 
617-983-6940	
https://www.mass.gov/fact-sheets-on-infectious-diseases 
 
HIV/AIDS	Reporting	for	Health	Care	Providers	
Brochure 
617-983-6560	
http://www.mass.gov/eohhs/gov/departments/dph/programs/
id/hiv-aids/reporting/	 
STD,	and	HIV	Posters	and	Brochures 617-983-6800	https://massclearinghouse.ehs.state.ma.us/	 
STD	Diagnosis,	Treatment,	and		
Management	Toolkits 
617-983-9645	
www.RatellePTC.org	
MDPH	and	MDPH	Funded	Websites		
Division	of	STD	Prevention	 	 	 www.mass.gov/dph/cdc/std	
HIV/AIDS	Bureau	 	 	 	 	 www.mass.gov/dph/aids	
HIV/AIDS	Surveillance	 	 	 	 www.mass.gov/dph/cdc/aids	
Viral	Hepatitis	Programs	 	 	 	 https://www.mass.gov/hepatitis-a 
https://www.mass.gov/hepatitis-b-hbv 
https://www.mass.gov/hepatitis-c-hcv  
Sylvie	Ratelle	STD/HIV	Prevention	Training	Center	 www.RatellePTC.org	
National	Websites		
Center	for	Disease	Control	and	Prevention	 	 www.cdc.gov	
Division	of	STD	Prevention	 	 www.cdc.gov/std	
Division	of	HIV/AIDS	Prevention	 	 www.cdc.gov/hiv	
Division	of	Viral	Hepatitis	 	 	 https://www.cdc.gov/hepatitis/index.htm	
National	Network	of	STD/HIV	Prevention		
Training	Centers	 	 	 	 www.nnptc.org	
